SELLAS Life Sciences Shares Soar 175% On Positive Phase 3 Cancer Trial Results
SELLAS Life Sciences (SLS) shares jumped 175% after reporting positive Phase 3 trial results for its cancer vaccine, GPS, in AML patients. The stock opened at $24.00, up from $7.47 the prior close, and traded between $1.39 and $24.89 over the past year.
How this was made
The 30-second read
Why it matters
A positive pivotal Phase 3 topline readout is a major de-risking event for biotech development programs and typically drives sharp repricing, especially when the market had priced in uncertainty.
Market read
Traders can act on a fresh, company-specific clinical catalyst that triggered a large same-day move.
What to watch
The article provides no details on magnitude of benefit, statistical significance, or safety; traders may fade gains ahead of full readouts and regulatory clarity.
Background
The company reported positive topline results from its pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML).
Ticker impact
SELLAS shares surged 175% after announcing positive topline Phase 3 REGAL trial results for its AML cancer vaccine galinpepimut-S.
Likely continued upside pressure and high volatility as traders price in potential regulatory and confirmatory-trial momentum.
The article attributes the outsized same-day move directly to positive Phase 3 topline results, a primary catalyst for biotech risk/reward repricing.
Market effects
Reinforces positive sentiment toward AML vaccine/immunotherapy development and can lift attention to similar late-stage oncology programs.
Primarily US small/mid-cap biotech sentiment, with spillover to broader biotech risk appetite.
Limited direct global impact beyond oncology trial-readthrough interest.
Counterpoint
Topline Phase 3 results can reverse on missing endpoints, safety signals, or weaker-than-expected effect sizes once full data are released.
Key entities
- companySELLAS Life Sciences Group, Inc.
Subject of the article; shares surged after positive Phase 3 topline results for its AML cancer vaccine.
- productGalinpepimut-S (GPS)
Investigational cancer vaccine evaluated in the pivotal Phase 3 REGAL trial.
- clinical_programREGAL trial
Phase 3 pivotal study in AML whose topline results were reported as positive.
- indicationAcute myeloid leukemia (AML)
Disease area targeted by the investigational vaccine in the trial.

